The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Taiwan shares close up 0.12%
12/26/2024 02:41 PM - Society
Taiwan headline news
12/26/2024 02:37 PM - Society
Rain expected Thursday in northern, northeastern Taiwan
12/26/2024 02:01 PM - Politics
TPP leader Ko Wen-je indicted on bribery, other corruption charges (update)
12/26/2024 01:47 PM - Society
Man sentenced to 10 years for stabbing attack on Taichung MRT
12/26/2024 12:36 PM